Clinical Trial Update: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension [Phase 3]

View source ↗

Summary

Open-label Phase 3 extension evaluating cardiovascular outcomes with PCSK9 inhibition in adults at elevated risk with dyslipidemia; study completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• PCSK9 inhibitors

Snippet

Sponsor: Amgen | Conditions: Dyslipidemia | Phase 3 | Status: COMPLETED | Results posted: 2023-02-28